Mountain West AIDS Education and Training Center (MWAETC)

OD presentation return node

« Return to MWAETC On-Demand Presentations

Long-acting Injectable Cabotegravir/Rilpivirine for Individuals Who Do Not Fulfill the FDA Eligibility Criteria

Presentation Date: 2022-10-20

Presentation Length: 24:38

Presenters: Brian Wood, MD

Presentation Categories: HIV ECHO

Presentation Tags: Anti-Retroviral Therapy (ART), Long- Acting ART/Injectables, Adherence

Presentation Slides:

Download (344.904 KB)

Presentation Downloads:

Related Documents:

Related Links:

Related Presentations:

Presentation Details:
Dr. Brian Wood reviews recent data and recommendations on use of long-acting, injectable cabotegravir/rilpivirine for individuals with significant challenges to oral ART, including individuals with detectable viral loads.

Presentation Transcript:

MOUNTAIN WEST AIDS EDUCATION AND TRAINING CENTER

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $2,982,063 with 0% financed with non-governmental sources. The content in presentations are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.